Stay updated on Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial page
- Check5 days agoChange DetectedAdded Lung cancer tag and related topics, including a link to MedlinePlus Genetics. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check13 days agoChange DetectedAdded a new Locations section featuring Quebec as a study site and removed the Quebec Locations listing. The page version notes show Revision: v3.3.3 added and Revision: v3.3.2 removed.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe page shows a new revision label, updating from v3.3.1 to v3.3.2, a maintenance/version update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check41 days agoChange DetectedRevision label in the page footer changed from v3.2.0 to v3.3.1; no changes to study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check49 days agoChange DetectedDeleted the recurring government funding status notice that warned users information may not be up to date and that inquiries could be delayed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check56 days agoChange DetectedRemoved Lung cancer and MedlinePlus Genetics from the related topics section on the study page.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial page.